Core Viewpoint - Growth investors are increasingly focused on identifying stocks with above-average financial growth, which can lead to solid returns, but finding such stocks is challenging due to their inherent risks and volatility [1] Group 1: Company Overview - McKesson is identified as a promising growth stock, supported by a favorable Growth Score and a top Zacks Rank [2] - The company has a historical EPS growth rate of 16%, with projected EPS growth of 12.6% this year, significantly outperforming the industry average of 1.3% [5] - McKesson's sales are expected to grow by 13% this year, compared to the industry average of 1.1% [7] Group 2: Key Metrics - The asset utilization ratio for McKesson is 4.95, indicating that the company generates $4.95 in sales for every dollar in assets, which is substantially higher than the industry average of 0.72 [6] - The current-year earnings estimates for McKesson have been revised upward, with the Zacks Consensus Estimate increasing by 0.1% over the past month [9] Group 3: Investment Potential - McKesson has achieved a Zacks Rank of 2 (Buy) and a Growth Score of A, indicating its potential as an outperformer and a solid choice for growth investors [11]

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even though momentum is a popular stock char ...

Core Viewpoint - Growth stocks are appealing due to their potential for above-average financial growth, but identifying strong candidates can be challenging due to associated risks and volatility [1] Group 1: Company Overview - McKesson (MCK) is highlighted as a recommended growth stock, possessing a favorable Growth Score and a top Zacks Rank [2] - The company has a historical EPS growth rate of 16%, with projected EPS growth of 12.5% this year, surpassing the industry average of 8.2% [4] Group 2: Key Growth Metrics - The asset utilization ratio for McKesson is 4.95, indicating that the company generates $4.95 in sales for every dollar in assets, significantly higher than the industry average of 0.77 [5] - McKesson's sales are expected to grow by 13% this year, compared to the industry average of 3.2% [6] Group 3: Earnings Estimate Revisions - There is a positive trend in earnings estimate revisions for McKesson, with the current-year earnings estimates increasing by 1.7% over the past month [7] Group 4: Investment Positioning - McKesson has achieved a Growth Score of A and a Zacks Rank of 2, positioning it well for potential outperformance in the growth stock category [9]

Now you can get access to the latest and highest-quality analysis of recent Wall Street buying and selling ideas with just one subscription to Beyond the Wall Investing ! There is a free trial and a special discount of 10% for you. Join us today!According to some of its own SEC filings , Hims & Hers Health (NYSE: HIMS ) is a telehealth firm that provides direct access to medical consultations and prescription drugs for a variety of cases throughDaniel Sereda is chief investment analyst at a family office wh ...

Company Performance - McKesson reported quarterly earnings of $10.12 per share, exceeding the Zacks Consensus Estimate of $9.81 per share, and up from $6.18 per share a year ago, representing an earnings surprise of 3.16% [1] - The company posted revenues of $90.82 billion for the quarter ended March 2025, which missed the Zacks Consensus Estimate by 3.08%, compared to $76.36 billion in the same quarter last year [2] - Over the last four quarters, McKesson has surpassed consensus EPS estimates three times and topped consensus revenue estimates only once [2] Stock Performance - McKesson shares have increased approximately 26.8% since the beginning of the year, while the S&P 500 has declined by 4.3% [3] - The current Zacks Rank for McKesson is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Future Outlook - The consensus EPS estimate for the upcoming quarter is $8.33 on revenues of $93.61 billion, and for the current fiscal year, it is $36.58 on revenues of $399.57 billion [7] - The outlook for the Medical - Dental Supplies industry, where McKesson operates, is currently in the top 34% of over 250 Zacks industries, suggesting a favorable environment for stock performance [8]

Core Insights - Journey Medical Corporation will release its first quarter 2025 financial results on May 14, 2025, after U.S. financial markets close [1] - A conference call and audio webcast will be held on the same day at 4:30 p.m. ET to discuss the financial results and provide a corporate update [1] Company Overview - Journey Medical Corporation is a commercial-stage pharmaceutical company focused on selling and marketing FDA-approved prescription products for dermatological conditions [4] - The company currently markets eight FDA-approved prescription drugs and has a team of industry experts with extensive experience in dermatology [4] - Journey Medical is based in Scottsdale, Arizona, and was founded by Fortress Biotech, Inc. [4]

Henry Schein (HSIC) came out with quarterly earnings of $1.15 per share, beating the Zacks Consensus Estimate of $1.11 per share. This compares to earnings of $1.10 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 3.60%. A quarter ago, it was expected that this health care products maker would post earnings of $1.19 per share when it actually produced earnings of $1.19, delivering no surprise.Over the last four quarters, the co ...

Core Viewpoint - Mobile-health Network Solutions (MNDR) intends to acquire Lifepack, a leading pharmacy and telehealth platform in Indonesia, to expand its presence in the high-growth Indonesian healthcare market [1][2][5]. Group 1: Acquisition Details - The acquisition of Lifepack is valued at up to US$7.2 million, contingent upon Lifepack achieving its revenue target for 2025 [5]. - The consideration will be satisfied through the issuance of up to 875,000 new MNDR Class A Ordinary Shares at an issue price of US$8 per share, along with a non-refundable cash payment of US$0.2 million [5][7]. - The US$8 per share issue price represents a substantial premium to MNDR's current share price of approximately US$1.42 as of April 29, 2025, indicating the perceived value of the acquisition [5]. Group 2: Strategic Importance - The acquisition aligns with Indonesia's primary care needs and complements MNDR's telehealth expertise, aiming to serve 280 million people across 17,000 islands [2][3]. - Lifepack's platform is compliant with BPOM regulations and is positioned to lead the Indonesian digital pharmacy market, enhancing healthcare access, especially in remote areas [4][3]. - The partnership aims to create a transformative online-to-offline (O2O) healthcare platform that addresses the unique needs of Indonesia's diverse population [3][4]. Group 3: Lifepack's Operations - Lifepack operates a hybrid model delivering BPOM-licensed prescription drugs, over-the-counter medications, supplements, and medical equipment through both online and offline channels [3][9]. - The platform offers consultations with healthcare professionals via its mobile app, website, and social media, supported by an expanding warehouse network [3][9]. - Lifepack focuses on chronic disease management and preventive care, addressing the growing demand for affordable medical services in Indonesia [3][4].